stockrow
Monday 9 November 2026
Export MGNX’s income statement to Excel — free account
MacroGenics, Inc.
MGNXMacroGenics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.5 million, roughly unchanged from fiscal 2024.
- Revenue
- +47.6%
- EPS
- +154.4%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
2.33
0.11
+4.95%
Follow MGNX
Alert me
MacroGenics, Inc. (MGNX) P/E ratio
MacroGenics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 146× (June 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 146×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGEN NervGen Pharma Corp. compare | n/m |
| MGNX MacroGenics, Inc. | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | — |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)